The 2022 Tandem Meetings | Impact of prior tafasitamab treatment on subsequent CD19-directed CAR-T therapy
Reona Sakemura
• 24 Apr 2022
Reona Sakemura, MD, PhD, Mayo Clinic, Rochester, MN, talks on the results of a study investigating the impact of prior CD19-targeting monoclonal antibody treatment with tafasitamab on subsequent treatment with CD19-directed CAR-T therapy. The study reported that prior tafasitamab treatment resulted in delayed CAR-T expansion and reduced CAR-T apoptosis in mouse models, and suggested that sequential therapy may reduce CAR-T toxicity. This interview took place at the Transplantation & Cellular Therapy (TCT) Meetings of ASTCT™ and CIBMTR® 2022 in Salt Lake City, Utah.
